ClinicalTrials.gg
RecruitingNCT07597005Updated May 19, 2026

Red Propolis Supplementation as a Strategy in Chronic Kidney Disease

An interventional study of Red Propolis and Placebo Control in Kidney Disease, Oxidative Stress and Chronic Kidney Disease, sponsored by Universidade Federal Fluminense. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Universidade Federal Fluminense · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2025, registered May 2026).
  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Kidney Diseases with a site in Brazil — 5 open to participants now, 11 under way, 8 of them phase 3. Kidney Diseases · Brazil.

Planned enrollment
21st of 24
40 · median 394
Started
2025
with 1 other
No phase
4 of 30
1 open now
Primary completion
2025-11
later than 2 of 10 live
Registered
30th of 30
by date
Lead sponsor
2 of 30
Universidade Federal Fluminense

Among the 30 studies in Kidney Diseases with a site in Brazil, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 30th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 185 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

5 of the 30 studies in Kidney Diseases with a site in Brazil are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 131 Kidney Diseases studies recruiting now, 77 (59%) set no upper age limit and 34 (26%) stop at 75 or younger; 27 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Kidney Diseases with a site in Brazil, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.

Read the detailed description

Chronic kidney disease (CKD) is associated with chronic systemic inflammation and oxidative stress, which contribute to disease progression and adverse outcomes. Red propolis is a natural substance rich in bioactive compounds with potential anti-inflammatory and antioxidant effects. Clinical evidence on its use in CKD patients is limited, and no studies have evaluated its impact on gene expression related to inflammation and oxidative stress. This randomized, double-blind, placebo-controlled trial will assess the effects of alcoholic extract of red propolis (200 mg/day for 8 weeks) on inflammatory and oxidative stress markers in patients with CKD stages 3-5 under conservative management. Blood samples will be collected at baseline and after intervention to evaluate routine biochemical parameters, inflammatory and oxidative stress markers, and gene expression. Nutritional status and dietary intake will also be assessed.

03

Conditions studied

  • Kidney Disease
  • Oxidative Stress
  • Chronic Kidney Disease
  • Inflammation

Keywords

  • oxidative stress
  • red propolis
  • inflammation
  • chronic kidney disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with CKD stages 3-5 under conservative management

Exclusion criteria

Exclusion Criteria:

  • pregnant,
  • lactating,
  • smoker
  • patients using antibiotics and antioxidant supplements in the last three months
  • patients with and infectious diseases,
  • patients with cancer, liver disease, and AIDS
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Red Propolis Group

    Patients with chronic kidney disease will receive capsules containing 200mg of red propolis / day for two months.

    Dietary Supplement: Red Propolis

  • Placebo comparator
    Placebo Group

    Patients with chronic kidney disease will receive capsules containing 200mg of placebo/ day for two months.

    Other: Placebo Control

Interventions

  • Dietary supplementRed Propolis

    Participants will receive 200mg of red propolis capsules per day for two months.

  • OtherPlacebo Control

    Participants will receive 200mg of placebo capsules per day for two months.

06

What researchers measure

Primary outcomes

  1. Change in inflammatory biomarkers

    Changes in the IL-6 and TNF-α

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Nov 2025, 2 months.

Of 127 non-industry interventional studies with no phase under Kidney Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 52. This study's 2 months is below that.

Counting every sponsor, half of 147 studies reached it within 34 months; a quarter within 13 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 19, 2026
StartActual
Sep 30, 2025
Primary completionActual
Nov 30, 2025
CompletionEst.
Aug 31, 2027
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07597005
Lead sponsor
Universidade Federal Fluminense
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Sep 30, 2025
Primary completion
Nov 30, 2025
Completion
Aug 31, 2027 (estimated)
Last update
May 19, 2026

Study contacts

Denise Mafra, phd
Contact
dmafra30@gmail.com
21985683003

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion